Cybin Inc. (CYBN)

Business: Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders.

IPO Date: 13-Sep-2019

Co-Founder, Pres & Exec. Chairman: Mr. Eric So L.L.B., LLB

Chief Exec. Officer: Mr. Douglas L. Drysdale

Listing: NYSE: CYBN

Country: Canada

Headquarters: Toronto, ON

Website: https://www.cybin.com

Market cap: $100.38 Mln

Revenue (TTM): CA$0.00 Mln

Earnings (TTM): CA$-63.31 Mln

Cash: CA$63.58 Mln

Total Debt: CA$0.00 Mln

Insider's Holding: 22.40%

Liquidity: Low

52 Week range: $0.39 - 3.38

Shares outstanding: 163,220,992